Conference Coverage

Switching to tenofovir alafenamide may benefit HBV patients


 

EXPERT ANALYSIS FROM DIGESTIVE DISEASES: NEW ADVANCES


Tenofovir alafenamide is not yet listed in the official recommendations of the American Association for the Study of Liver Diseases, but it is in current guidelines from the European Association for the Study of the Liver.

The published EASL guidelines provide guidance on how tenofovir alafenamide fits into the treatment armamentarium for HBV.

Going by the EASL recommendations, age greater than 60 years, bone disease, and renal alterations are all good reasons to use tenofovir alafenamide as first-line therapy for hepatitis B, according to Dr. Kwo.

Dr. Kwo reported disclosures related to AbbVie, Allergan, Bristol-Myers Squibb, Conatus Pharmaceuticals, Dova Pharmaceuticals, DURECT, Gilead Sciences, Merck, and Shionogi.

Global Academy and this news organization are owned by the same company.

Next Article: